Thirty thousand doses of Regeneron Pharmaceuticals Inc.’s antibody cocktail will be shipped Tuesday, after the experimental coronavirus treatment got an emergency authorization from U.S. regulators.
Health and Human Services Secretary Alex Azar detailed plans to distribute the therapy at a news conference on Monday. The drug, called REGN-COV2, received clearance from the U.S. Food and Drug Administration for treatment of mild to moderate COVID-19 in adults and some children of at least 12 years of age.
Earlier this year, Regeneron agreed to a US$450 million supply deal with Operation Warp Speed, the U.S. program to accelerate the development of vaccines and treatments for COVID-19. The treatment was given to President Donald Trump last month after he contracted the virus.
Regeneron said on Saturday that it expects to have treatment doses of its drug ready for approximately 80,000 patients by the end of this month, about 200,000 patients by the first week of January, and about 300,000 patients total by the end of January.
Shares of Regeneron were up 0.5 per cent at US$521.09 at 2:18 p.m. on Monday.
Advertisement